328 related articles for article (PubMed ID: 29431852)
21. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.
Tidey JW; Monti PM; Rohsenow DJ; Gwaltney CJ; Miranda R; McGeary JE; MacKillop J; Swift RM; Abrams DB; Shiffman S; Paty JA
Alcohol Clin Exp Res; 2008 Jan; 32(1):58-66. PubMed ID: 18028530
[TBL] [Abstract][Full Text] [Related]
22. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.
Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR
Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981
[TBL] [Abstract][Full Text] [Related]
23. Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.
Roche DJO; Trela CJ; Argos M; Jasmine F; Kibriya MG; Ahsan H; King AC
Alcohol Alcohol; 2019 Jan; 54(5):559-565. PubMed ID: 31206155
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
[TBL] [Abstract][Full Text] [Related]
25. Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
Green R; Bujarski S; Lim AC; Venegas A; Ray LA
Exp Clin Psychopharmacol; 2019 Jun; 27(3):257-264. PubMed ID: 30628813
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
27. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
28. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
30. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
31. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.
O'Malley SS; Zweben A; Fucito LM; Wu R; Piepmeier ME; Ockert DM; Bold KW; Petrakis I; Muvvala S; Jatlow P; Gueorguieva R
JAMA Psychiatry; 2018 Feb; 75(2):129-138. PubMed ID: 29261824
[TBL] [Abstract][Full Text] [Related]
32. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS; Corbin WR; Leeman RF; DeMartini KS; Fucito LM; Ikomi J; Romano DM; Wu R; Toll BA; Sher KJ; Gueorguieva R; Kranzler HR
J Clin Psychiatry; 2015 Feb; 76(2):e207-13. PubMed ID: 25742208
[TBL] [Abstract][Full Text] [Related]
33. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine.
Ray R; Jepson C; Patterson F; Strasser A; Rukstalis M; Perkins K; Lynch KG; O'Malley S; Berrettini WH; Lerman C
Psychopharmacology (Berl); 2006 Oct; 188(3):355-63. PubMed ID: 16960700
[TBL] [Abstract][Full Text] [Related]
34. Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.
Garbutt JC; Kampov-Polevoy AB; Kalka-Juhl LS; Gallop RJ
JAMA Psychiatry; 2016 Oct; 73(10):1056-1063. PubMed ID: 27627782
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
[TBL] [Abstract][Full Text] [Related]
36. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Fucito LM; Park A; Gulliver SB; Mattson ME; Gueorguieva RV; O'Malley SS
Biol Psychiatry; 2012 Nov; 72(10):832-8. PubMed ID: 22541040
[TBL] [Abstract][Full Text] [Related]
37. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.
Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H
Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071
[TBL] [Abstract][Full Text] [Related]
38. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist?
Baros AM; Latham PK; Anton RF
Alcohol Clin Exp Res; 2008 May; 32(5):771-6. PubMed ID: 18336635
[TBL] [Abstract][Full Text] [Related]
39. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
[TBL] [Abstract][Full Text] [Related]
40. Genetic moderators of naltrexone's effects on alcohol cue reactivity.
McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R
Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
